Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Mar;14(3):595-598.
doi: 10.21037/jtd-22-64.

Treatment selection with organoids in an EGFRm + TP53m stage IA1 patient with recurrence after radical surgery

Yoshikane Yamauchi  1 , Yuichi Saito  1
Affiliations
Editorial

Treatment selection with organoids in an EGFRm + TP53m stage IA1 patient with recurrence after radical surgery

Yoshikane Yamauchi et al. J Thorac Dis. 2022 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-64/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77. 10.1056/NEJMoa1408440 - DOI - PubMed
    1. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141-51. 10.1016/S1470-2045(14)71173-8 - DOI - PubMed
    1. Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw 2021;19:254-66. 10.6004/jnccn.2021.0013 - DOI - PubMed
    1. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 2020;31:1491-505. 10.1016/j.annonc.2020.07.014 - DOI - PubMed
    1. Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer 2019;19:495-509. 10.1038/s41568-019-0179-8 - DOI - PMC - PubMed